Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c, Offers FY19 Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.94, $0.09 better than the analyst estimate of $0.85. Revenue for the quarter came in at $5.97 billion versus the consensus estimate of $5.99 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2019 EPS of $4.10-$4.20, versus the consensus of $4.14.

• Worldwide revenues increasing in the mid-single digits.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Dare Bioscience (DARE) Tops Q2 EPS by 11c